Search Medical Condition
Please enter condition
Please choose location from dropdown
Clear Trial Filters
 

Juvisy sur Orge, France Clinical Trials

A listing of Juvisy sur Orge, France clinical trials actively recruiting patients volunteers.

RESULTS

Found (61) clinical trials

Study Of OX40 Agonist PF-04518600 Alone And In Combination With 4-1BB Agonist PF-05082566

To assess the safety and tolerability at increasing dose levels of PF-04518600 alone or in combination wtih PF-05082566 in patients with select advanced or metastatic carcinoma in order to determine the maximum tolerated dose and select the recommended Phase 2 dose.

Phase

7.0 miles

Learn More »

A Phase I Study of a Therapeutic Vaccine Candidate in Patients With Localized Breast Cancer at High-Risk of Relapse

This study is a three dose level open-label, non-randomized, dose-escalation study Phase I of the safety of the vaccine candidate MAG-Tn3 + AS15 administered to patients with HER2 negative, high-risk localized breast cancer in remission. A maximum of 30 patients will be included in the study: 3 or 6 patients ...

Phase

7.0 miles

Learn More »

Study of TSR-033 With an Anti-PD-1

This is a multi-center, open-label, first-in-human, Phase 1 study evaluating the anti-LAG-3 antibody of TSR-033 alone and in combination with anti-PD-1. The study will be conducted in 2 parts, with Part 1 consisting of dose escalation to determine the RP2D of TSR-033 as a single agent (Part 1a) and in ...

Phase

7.0 miles

Learn More »

A Study to Investigate Biomarker Effects of Pre-Surgical Treatment With DNA Damage Repair (DDR) Agents in Patients With Head and Neck Squamous Cell Carcinoma (HNSCC)

Patients are dosed for a minimum of nine days with drug. Surgery or biopsy can then take place at any time between Day 10 and Day 21 (depending on when it can be scheduled), but must occur with 24 hrs following three consecutive treatment days. During the treatment period, safety ...

Phase

7.0 miles

Learn More »

Study of S 95005 in Combination With Oxaliplatin in Metastatic Colorectal Cancer

This is a one-arm study, which will be conducted in 2 parts: A dose-escalation part to determine the Maximum Tolerated Dose (MTD) of S 95005 in combination with oxaliplatin. An expansion part in patients treated at the recommended dose defined in the dose escalation part of this study to evaluate ...

Phase

7.0 miles

Learn More »

MCLA-117 in Acute Myelogenous Leukemia

Study Design : This open label, single arm, multinational, first-in-human study consists of 2 parts. Part 1 consists of dose escalation cohorts and Part 2 is a dose expansion cohort. The study population will include adult AML patients (and all subtypes of AML) with relapse or refractory disease and newly ...

Phase

7.0 miles

Learn More »

Panobinostat and Ruxolitinib in Primary Myelofibrosis Post-polycythemia Vera-myelofibrosis or Post-essential Thrombocythemia-myelofibrosis

This study will assess safety as well as establish a Recommended Phase II dose of the combination of panobinostat and ruxolitinib in patients with or without the JAK2V617F mutation who have been diagnosed with primary myelofibrosis (PMF), Post Essential Thrombocythemia Myelofibrosis (PET MF), or Post-Polycythemia Vera Myelofibrosis (PPV MF).

Phase

7.0 miles

Learn More »

Study to Investigate Safety Pharmacokinetic (PK) Pharmacodynamic (PD) and Clinical Activity of Trametinib in Subjects With Cancer or Plexiform Neurofibromas and Trametinib in Combination With Dabrafenib in Subjects With Cancers Harboring V600 Mutations

This is a 4-part (Part A, Part B, Part C and Part D), Phase I/IIa, multi-center, open label, study in pediatric subjects with refractory or recurrent tumors. Part A is a repeat dose, dose escalation monotherapy study that will identify the recommended phase II dose (RP2D) on the continuous dosing ...

Phase

7.18 miles

Learn More »

MEDI4736 Alone and in Combination With Tremelimumab or AZD9150 in Adult Subjects With Relapsed/Refractory DLBCL (D4190C00023)

This is a multicenter, open-label, dose-escalation and dose-expansion study of MEDI4736 (durvalumab) as monotherapy or in combination with either tremelimumab or AZD9150. The objectives are to describe any dose-limiting toxicities, determine the maximum tolerated dose, and evaluate the safety, tolerability, efficacy, immunogenicity, pharmacokinetics, and pharmacodynamics of MEDI4736 as monotherapy or ...

Phase

7.18 miles

Learn More »

To determine the safety, tolerability, pharmacokinetics, maximum tolerated dose, or pharmacological active dose of BAY2402234 in patients with acute myeloid leukemia (AML), myelodysplastic syndrome (MDS), or chronic myelomonocytic leukemia (CMML)

Phase

7.18 miles

Learn More »